Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

67%(2 trials)

Phase Distribution

Ph phase_1

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_2

Efficacy of VTP-300 in Chronic Hepatitis B Infection

NCT05343481

completedphase_1

First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection

NCT04297917

completedphase_1

First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

NCT04778904

Clinical Trials (3)

Showing 3 of 3 trials

NCT05343481Phase 2

Efficacy of VTP-300 in Chronic Hepatitis B Infection

Completed

NCT04297917Phase 1

First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection

Completed

NCT04778904Phase 1

First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

Completed

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3